Vanguard Capital Management
RNAC icon

Vanguard Capital Management’s Cartesian Therapeutics RNAC Stock Holding History

Vanguard Capital Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.79M Buy
555,823
+148,226
+36% +$1.1M ﹤0.01% 3066
2026
Q1 		$2.51M Buy
+407,597
New +$2.9M ﹤0.01% 3288

Other funds holding RNAC

Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Vanguard Capital Management's RNAC Position: Q2 2026 in Review

Vanguard Capital Management increased its Cartesian Therapeutics (RNAC) stake by 36% in Q2 2026, buying an estimated $1.1M and bringing the position to 555,823 shares worth $5.79M. The position accounts for ﹤0.01% of the portfolio, ranked #3066.

Vanguard Capital Management first reported a position in RNAC in Q1 2026 and has held it in 2 quarters since. 95 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

  • Vanguard Capital Management held 555,823 shares of Cartesian Therapeutics worth $5.79M as of Q2 2026.
  • Vanguard Capital Management bought 148,226 Cartesian Therapeutics shares in Q2 2026, an estimated $1.1M.
  • Cartesian Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3066 holding.
  • Vanguard Capital Management first reported a position in Cartesian Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.